Lu AH69593

**Lu AH69593** is an investigational **small-molecule** drug candidate being developed by **Lundbeck** for **narcolepsy**. Publicly available clinical-trial records identify it as a Phase 1 program that has been studied both alone in adults who are healthy or have narcolepsy and in a separate first-in-human study alongside another Lundbeck candidate, Lu AH70212. The precise chemical identity, INN, dosage form, route, and validated molecular target have not been publicly disclosed in the sources reviewed. Given Lundbeck's contemporaneous narcolepsy research focus and patent activity around **orexin receptor 2 agonists**, Lu AH69593 is plausibly a wake-promoting CNS program in that area, but the exact mechanism for this specific code has not been confirmed publicly and therefore should be treated as undisclosed.